Inhibitors of human tumor-expressed ccxckr2
AssigneeChemoCentryx, Inc.
InventorsAnita Melikian, Jennifer Burns, Brian E. McMaster, Thomas Schall, John J. Wright
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.
Claims38
A modulator of the structure (I), or a salt thereof:
- where m is an integer from 1 to 5;
- each Y is independently selected from the group consisting of hydrogen, halogen, —CN, —NO2, —OH, —OR′, —C(O)R′, —CO2R′, —O(CO)R′, —C(O)NR′R″, —OC(O)NR′R″, —SR′, —SOR′, —SO2R′, —SO2NR′R″, —NR′R″, —NR′C(O)R″, —NR′C(O)2R′, —NR′SO2R″, —NR′(CO)NR″R″, unsubstituted or substituted C1-8 alkyl, unsubstituted or substituted C2-8 alkenyl, unsubstituted or substituted C2-8 alkynyl, unsubstituted or substituted C3-8 cycloalkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, and unsubstituted or substituted 3- to 10-membered heterocyclyl;
- where each R′, R″ and R′″ are independently hydrogen, halogen, unsubstituted or substituted C1-8 alkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, and unsubstituted or substituted 3- to 10-membered heterocyclyl;
- n is 0, 1, 2 or 3;
- Z is —CHR1R2—, —OR1, or —NR1R2;
- R1 and R2 are each independently substituted or unsubstituted alkyl or hydrogen, or Z in combination with R1 and R2 form a substituted or unsubstituted 5- to 8-membered ring comprising at least one nitrogen and 0 to 3 additional heteroatoms;
- R6 is alkyl, hydrogen, or halogen;
- and
- R3, R4, and R5 are each independently selected from the group consisting of hydrogen, halogen, —CN, —NO2, —OH, —OR′, —C(O)R′, —CO2R′, —O(CO)R′, —C(O)NR′R″, —OC(O)NR′R″, —SR′, —SOR′, —SO2R′, —SO2NR′R″, —NR′R″, —NR′C(O)R″, —NR′C(O)2R″, —NR′SO2R″, —NR′(CO)NR″R′″, unsubstituted or substituted C1-8 alkyl, unsubstituted or substituted C2-8 alkenyl, unsubstituted or substituted C2-8 alkynyl, unsubstituted or substituted C3-8 cycloalkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, and unsubstituted or substituted 3- to 10-membered heterocyclyl, or where any two of R3, R4 or R5 together with the atoms which they substituted form a substituted or unsubstituted 3- to 10-membered heterocycyl.
A modulator having the structure (II):
- where n=0-4
- where each Y is independently hydrogen or halogen;
- R3, R4, and R5 are each independently R3, R4, and R5 are each independently selected from the group consisting of hydrogen, halogen, and —OR′;
- or any two of R3, R4, and R5, together with the atoms which they substituted, form unsubstituted or substituted 3- to 10-membered heterocyclyl;
- and
- R7 is selected from the group consisting of hydrogen, —C(O)R′, —CO2R′, —C(O)NR′R″, —SO2R′, unsubstituted or substituted C1-8 alkyl (optionally C1-8 alkoxyalkyloxy, CH2CH2OCH2CH2OMe)alkyl, unsubstituted or substituted C2-8 alkenyl, unsubstituted or substituted C2-8 alkynyl, unsubstituted or substituted C3-8 cycloalkyl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, and unsubstituted or substituted 3- to 10-membered heterocyclyl.
A modulator comprising one of the following formulae:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
A pharmaceutical composition comprising a compound of the formulae:
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.